基于分子标志物检测的晚期卵巢癌中PARPi的精准治疗  

Precision therapy of PARPi in advanced ovarian cancer based on molecular markers detection

作　　者：陈倩莹 刘立峰[1] 金仙玉 CHEN Qianying;LIU Lifeng;JIN Xianyu(Department of Gynecology and Obstetrics,Dalian Central Hospital Affiliated to Dalian University of Technology,Dalian 116033,China)

机构地区：[1]大连理工大学附属大连市中心医院妇产科,辽宁大连116033

出　　处：《大连医科大学学报》2024年第1期67-73,共7页Journal of Dalian Medical University

摘　　要：聚腺苷二磷酸核糖聚合酶抑制剂(PARPi)的出现改变了卵巢癌治疗的格局,形成了手术联合含铂化疗以及维持治疗的新模式,有效改善了晚期卵巢癌的预后。本文系统性概括了PARPi在基于分子标志物检测的晚期卵巢癌患者中新辅助治疗,一线维持治疗,复发后二线治疗的最新临床试验研究结果,尤其是PARPi维持治疗后再次使用PARPi或化疗,以确定最有可能从PARPi治疗中受益的患者,并指导治疗决策。The emergence of poly(ADP-ribose)polymerase inhibitors(PARPi)has changed the landscape of ovarian cancer treatment,forming a new model of surgery combined with platinum containing chemotherapy and maintenance therapy,effectively improving the prognosis of advanced ovarian cancer.This article systematically summarizes the latest clinical trial results of PARPi in advanced ovarian cancer patients based on molecular marker detection,including neoadjuvant therapy,firstline maintenance therapy,and second-line treatment after recurrence,especially the use of PARPi or chemotherapy after PARPi maintenance therapy,to determine patients most likely to benefit from PARPi treatment and guide treatment decisions.

关 键 词：卵巢癌 PARPi BRCA 同源重组修复缺陷 

分 类 号：R737.31[医药卫生—肿瘤]